Research Analysts Set Expectations for PRQR Q2 Earnings

ProQR Therapeutics N.V. (NASDAQ:PRQR) – Equities research analysts at HC Wainwright issued their Q2 2026 earnings estimates for ProQR Therapeutics in a research note issued to investors on Monday, March 16th. HC Wainwright analyst A. Ghosh expects that the biopharmaceutical company will post earnings of ($0.13) per share for the quarter. The consensus estimate for ProQR Therapeutics’ current full-year earnings is ($0.31) per share. HC Wainwright also issued estimates for ProQR Therapeutics’ Q3 2026 earnings at ($0.09) EPS, Q4 2026 earnings at ($0.09) EPS, FY2026 earnings at ($0.43) EPS, FY2027 earnings at ($0.42) EPS, FY2028 earnings at ($0.27) EPS and FY2029 earnings at ($0.13) EPS.

Other research analysts have also issued research reports about the company. Wall Street Zen raised ProQR Therapeutics from a “strong sell” rating to a “hold” rating in a report on Saturday, March 14th. Oppenheimer initiated coverage on shares of ProQR Therapeutics in a research report on Thursday, March 12th. They set an “outperform” rating and a $9.00 target price on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of ProQR Therapeutics in a research note on Thursday, January 22nd. Finally, Citigroup reiterated a “market outperform” rating on shares of ProQR Therapeutics in a report on Friday, March 13th. Six analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $6.80.

ProQR Therapeutics Price Performance

PRQR opened at $1.72 on Wednesday. The business has a 50 day simple moving average of $1.62 and a 200-day simple moving average of $2.06. The stock has a market capitalization of $181.22 million, a P/E ratio of -3.74 and a beta of 0.21. ProQR Therapeutics has a 12 month low of $1.07 and a 12 month high of $3.10.

ProQR Therapeutics (NASDAQ:PRQR) last announced its quarterly earnings data on Thursday, March 12th. The biopharmaceutical company reported ($0.09) EPS for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.01). ProQR Therapeutics had a negative net margin of 255.83% and a negative return on equity of 65.89%. The firm had revenue of $5.50 million during the quarter, compared to analyst estimates of $6.12 million.

Hedge Funds Weigh In On ProQR Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the company. Privium Fund Management B.V. boosted its position in ProQR Therapeutics by 7.2% during the fourth quarter. Privium Fund Management B.V. now owns 5,357,762 shares of the biopharmaceutical company’s stock worth $10,823,000 after purchasing an additional 359,475 shares in the last quarter. Affinity Asset Advisors LLC increased its position in shares of ProQR Therapeutics by 6.5% in the second quarter. Affinity Asset Advisors LLC now owns 3,499,512 shares of the biopharmaceutical company’s stock valued at $7,139,000 after buying an additional 215,000 shares in the last quarter. Aberdeen Group plc increased its position in shares of ProQR Therapeutics by 28.4% in the fourth quarter. Aberdeen Group plc now owns 2,950,676 shares of the biopharmaceutical company’s stock valued at $5,960,000 after buying an additional 651,853 shares in the last quarter. Sio Capital Management LLC raised its stake in shares of ProQR Therapeutics by 1.0% during the 2nd quarter. Sio Capital Management LLC now owns 2,075,139 shares of the biopharmaceutical company’s stock worth $4,233,000 after buying an additional 20,546 shares during the last quarter. Finally, Ikarian Capital LLC raised its stake in shares of ProQR Therapeutics by 67.2% during the 4th quarter. Ikarian Capital LLC now owns 1,492,229 shares of the biopharmaceutical company’s stock worth $3,014,000 after buying an additional 600,000 shares during the last quarter. 32.65% of the stock is owned by institutional investors and hedge funds.

ProQR Therapeutics News Roundup

Here are the key news stories impacting ProQR Therapeutics this week:

• Positive Sentiment: HC Wainwright projects a long‑term recovery with a FY2030 EPS forecast of $0.18, implying management/program catalysts could deliver positive earnings by 2030 if clinical and commercial execution improve. HC Wainwright estimates / MarketBeat
• Neutral Sentiment: ProQR presented at The Citizens Life Sciences Conference (investor presentation transcript available). Presentations can increase visibility and clarify program timelines or trial readouts; see transcript for management comments on pipeline and strategy. Presentation Transcript
• Negative Sentiment: HC Wainwright sharply cut near‑ and medium‑term EPS estimates across 2026–2029 (e.g., FY2026 from ~($0.13) to ($0.43); FY2027 to ($0.42); FY2028 to ($0.27); FY2029 to ($0.13)) and lowered quarterly 2026 estimates — signaling weaker expected near‑term performance, slower commercialization or higher costs. Those downgrades increase downside pressure on the stock. HC Wainwright estimates / MarketBeat
• Negative Sentiment: Recent quarterly results (reported 3/12) missed consensus on EPS and revenue, and the company shows negative margins and ROE — a backdrop that makes the analyst cuts more meaningful and likely to weigh on investor sentiment. Earnings summary / MarketBeat

About ProQR Therapeutics

ProQR Therapeutics N.V. is a clinical-stage biotechnology company dedicated to developing RNA-based therapies for severe genetic diseases. Utilizing its proprietary Axiomer® RNA editing platform, ProQR aims to correct disease-causing mutations directly at the messenger RNA level. The company’s pipeline features several investigational candidates, including sepofarsen (formerly QR-110) for Leber congenital amaurosis type 10, QR-421a targeting Usher syndrome and certain forms of retinitis pigmentosa, and QR-313 for dystrophic epidermolysis bullosa.

Founded in 2012 and headquartered in Leiden, the Netherlands, ProQR maintains a significant presence in Cambridge, Massachusetts, to support its clinical research and regulatory initiatives.